Prognostic significance of the PC10 index for patients with stage II and III oesophageal cancer treated with radiotherapy.
The monoclonal antibody PC10 is used for immunohistochemical staining of the proliferating cell nuclear antigen (PCNA). The percentage of PC10-positive cancer cells is defined as the PC10 index. We evaluated the relationship between the PC10 index in pretreatment endoscopic biopsies and the prognoses of 47 patients with Stage II-III oesophageal squamous cell carcinoma treated with radiotherapy. The patients with a PC10 index > 40% had significantly poorer prognoses than the other patients (p = 0.0007). Proportional hazards model analysis indicated that only the PC10 index was a prognostic factor (p = 0.0009). The patient group of complete responders showed significantly lower PC10 indices compared to patients with a partial response or no change (p = 0.049). The PC10 index can be a good predictive indicator of the prognosis in patients with Stage II-III oesophageal cancer treated with radiotherapy.
Sugahara
S
S
Department of Radiology, Hitachi General Hospital, Hitachi-shi, Ibaraki, Japan. sugahara@cm.nichibyo.hitachi.co.jp
Ohara
K
K
Takahashi
A
A
Irie
T
T
Watanabe
T
T
Tanaka
N
N
Nozawa
K
K
Nakajima
K
K
Itai
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis* / Q000276:immunology; D012189:Retrospective Studies; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D018809:Proliferating Cell Nuclear Antigen